This company has an awful pipeline with no new drug of any value. Additionally, when earnings and script counts are released this stock will tank harder than Vivus did. I find it interesting it's been out since December and we have zero information with regards to actual sales or script counts. All we have is a bogus number of $19 million in 2 weeks after launch reported by forest. Well guess what, that was stocking and that $19 million worth of Linzess is sitting on pharmacy shelves collecting dust.
I work as a Retail pharmacist part time and full time as a consultant pharmacist in nursing homes full time. Since this drugs was approved I have never seen it used in a nursing home pt (which makes sense cause its so unpredictable it could kill a frail elderly person) and also have not seen it prescribed in retail. I even called a few of my pharmacist friends who work at busy stores and they tell me they don't stock it and haven't even heard of Linzess. Finally, go on IBS forums or read Linzess drug reviews online. 9 out of 10 reviews are negative saying either it didn't work or more frequently, caused unbearable diarrhea, bloating, or abdominal pain.
This company will continue bleeding cash and diluting shareholder value until Synergy get there drug approved and takes over the lions share of the market from Amitiza, not Linzess. Ironwood will slip into the abyss and trade someplace around the market cap of Succampo, around $200-300 million. Anyone who thinks Linzess will be a billion dollar drug is a fool. Less
Lol, this a freakin hilarious. Stock approaching a $2 billion market cap! Insiders selling and yet the stock gets meaningless upgrades and price continues to rise senselessly. When Q1 earning come in everyone will see the shame and illusion created. Royalty payments will be less than $1 million, probably closer to $500k if theyre lucky. On top of those awful earnings you will get a nice fat loss of between $80-90 million. Company esaid it themselves they expect to spen around $250-350 million. Price will crater to half it's value to around a $1 billion market cap, where it should be right now. After that you'll get a slow and continued bleed. This will drop faster than it rose!